Takeda Pharmaceutical (TAK) Expected to Announce Earnings on Thursday

Takeda Pharmaceutical (NYSE:TAK) is expected to release its Q3 2026 results before the market opens on Thursday, January 29th. Analysts expect Takeda Pharmaceutical to post earnings of $0.55 per share and revenue of $7.8144 billion for the quarter. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. Parties can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Thursday, January 29, 2026 at 5:30 AM ET.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.44. The firm had revenue of $7.30 billion during the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical had a return on equity of 10.32% and a net margin of 0.86%. On average, analysts expect Takeda Pharmaceutical to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Takeda Pharmaceutical Stock Up 1.8%

Takeda Pharmaceutical stock opened at $16.59 on Tuesday. Takeda Pharmaceutical has a fifty-two week low of $12.99 and a fifty-two week high of $16.62. The firm has a market capitalization of $52.79 billion, a price-to-earnings ratio of 207.38 and a beta of 0.03. The stock’s fifty day moving average is $15.18 and its two-hundred day moving average is $14.75. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.76 and a current ratio of 1.37.

Analysts Set New Price Targets

A number of brokerages recently commented on TAK. Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Morgan Stanley assumed coverage on shares of Takeda Pharmaceutical in a research report on Tuesday, January 13th. They issued an “overweight” rating on the stock. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Hold”.

Institutional Investors Weigh In On Takeda Pharmaceutical

Hedge funds have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. raised its position in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after buying an additional 1,292 shares during the last quarter. Advisory Services Network LLC purchased a new stake in Takeda Pharmaceutical in the 3rd quarter worth approximately $74,000. Larson Financial Group LLC raised its holdings in Takeda Pharmaceutical by 43.7% in the 3rd quarter. Larson Financial Group LLC now owns 7,823 shares of the company’s stock valued at $115,000 after acquiring an additional 2,379 shares during the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of Takeda Pharmaceutical during the 2nd quarter worth $174,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Takeda Pharmaceutical by 1,652.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 11,845 shares of the company’s stock worth $183,000 after purchasing an additional 11,169 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.